DarioHealth’s cardiometabolic solution shows healthy 12-month behavioral change

DarioHealth announced two new studies presented at the 84th Annual American Diabetes Association Scientific Sessions in Orlando. The first study provides an analysis of member data for those tracking a GLP-1 medication in Dario’s cardiometabolic solution. This new research confirms that behavior change driven by Dario’s digital platform is sustainable for a 12 month period and supports clinical results for members taking a GLP-1. Additional research demonstrates that 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission. The data showed significant improvement in adopting healthy behaviors over a 12-month period across both groups as shown by increased tracking of healthy lifestyle behaviors as shown by logged meals and physical activity beginning in the first three months and sustained through the 12-month period. Dario members using a GLP-1 also experienced additional improvements to outcomes and behavior change compared to the group using Metformin.